Inclusion Criteria:

          1. Patient must be at least 18 years old

          2. Patient must have given written informed consent

          3. Confirmed diagnosis of non-small cell lung cancer that is considered to be smoking
             related

          4. ECOG Performance status 0-1

          5. Anticipated life expectancy ≥ 6 months

          6. Measurable disease according to RECIST 1.1 criteria

          7. Adequate organ function

          8. Patient is considered medically fit to undergo procurement of starting material and
             ATL001 administration procedures

          9. Patient is considered, in the opinion of the investigator, capable of adhering to the
             protocol.

         10. If female, patient must be either postmenopausal, sterilised or, if sexually active,
             effectively practicing a highly effective method of contraception.

         11. Male patients agree to ensure that they or their female partner(s) use a highly
             effective method of contraception during the study

        Exclusion Criteria:

          1. Patients with evidence of CNS metastases

          2. Patients with active infectious disease

          3. Patients who are non-smokers

          4. Patients requiring immunosuppressive treatments.

          5. Patients requiring regular treatment with systemic steroids

          6. Patients with superior vena cava syndrome

          7. Patients with clinically significant, progressive, and/or uncontrolled renal, hepatic,
             haematological, endocrine, pulmonary, cardiac, gastroenterological or neurological
             disease

          8. Patients who are pregnant or breastfeeding

          9. Patients who have undergone major surgery in the previous 3 weeks

         10. Patients with an active concurrent cancer or a history of cancer within the past 3
             years (except for in situ carcinomas or non-melanomatous skin cancers)

         11. Patients with a history of organ transplantation.

         12. Patients who have received any investigational cell or gene therapies

         13. Patients with contraindications for protocol specified agents

         14. Patients with a history of immune mediated central nervous system toxicity with causal
             or suspected causal link to immunotherapy

        Additional exclusion criteria may apply to define procedures within the protocol